Romel Somwar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Romel Somwar has a total of 218 co-authors. Here are the top co-authors by number of shared publications:
- Marc Ladanyi
Memorial Sloan Kettering Cancer Center 1 Department of Pathology and Laboratory Medicine New York, New York
75 shared publications - Elisa de Stanchina
Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center, New York, NY, USA
49 shared publications - Filemon S. Dela Cruz
Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
32 shared publications - Soo-Ryum Yang
Memorial Sloan Kettering Cancer Center, New York, NY
32 shared publications - Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
26 shared publications - Michael Offin
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
22 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Partial ATM defects in Ewing sarcoma
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Partial ATM defects in Ewing sarcoma
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Genomic scar analysis from ES patient tumors
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Genomic scar analysis from ES patient tumors
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Note 4 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Discussion of heterogeneity in ATR inhibitor response
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Note 4 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Discussion of heterogeneity in ATR inhibitor response
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
In cancers with genetic loss of specific DNA damage response (DDR) genes (e.g., BRCA1/2 tumor-suppressor mutations), synthetic lethal targeting of compensatory DDR pathways has translated into clinical benefit for patients. Native FET family members are among the earliest factors recruited to DNA double-strand breaks (DSB), and FET fusion oncoproteins drive a diversity of sarcomas and leukemias. A better understanding of both native FET protein and FET fusion oncoprotein function in DNA repair could reveal tumor-specific vulnerabilities and provide therapeutic opportunities. In this study, we focus on Ewing sarcoma, a pediatric bone tumor driven by the FET fusion oncoprotein EWSR1::FLI1, as a model for FET-rearranged cancers. We discovered that recruitment of EWSR1::FLI1 and other FET fusion oncoproteins to DNA DSBs impairs the activation and downstream signaling of the DNA damage sensor ATM. The compensatory ATR signaling axis acts as a collateral dependency and therapeutic target in patient-derived xenograft models of multiple FET-rearranged cancers. In summary, these findings describe how oncogenes can disrupt physiologic DNA repair and provide the preclinical rationale for testing ATR inhibitors in FET-rearranged cancers as part of ongoing early-phase clinical trials.Significance:FET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields—oncogene biology and DNA repair—and proposing ATR inhibition as a targeted therapeutic approach for FET rearranged cancers.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
In cancers with genetic loss of specific DNA damage response (DDR) genes (e.g., BRCA1/2 tumor-suppressor mutations), synthetic lethal targeting of compensatory DDR pathways has translated into clinical benefit for patients. Native FET family members are among the earliest factors recruited to DNA double-strand breaks (DSB), and FET fusion oncoproteins drive a diversity of sarcomas and leukemias. A better understanding of both native FET protein and FET fusion oncoprotein function in DNA repair could reveal tumor-specific vulnerabilities and provide therapeutic opportunities. In this study, we focus on Ewing sarcoma, a pediatric bone tumor driven by the FET fusion oncoprotein EWSR1::FLI1, as a model for FET-rearranged cancers. We discovered that recruitment of EWSR1::FLI1 and other FET fusion oncoproteins to DNA DSBs impairs the activation and downstream signaling of the DNA damage sensor ATM. The compensatory ATR signaling axis acts as a collateral dependency and therapeutic target in patient-derived xenograft models of multiple FET-rearranged cancers. In summary, these findings describe how oncogenes can disrupt physiologic DNA repair and provide the preclinical rationale for testing ATR inhibitors in FET-rearranged cancers as part of ongoing early-phase clinical trials.Significance:FET fusion oncoproteins subvert genome maintenance by impairing ATM activity, bridging two key fields—oncogene biology and DNA repair—and proposing ATR inhibition as a targeted therapeutic approach for FET rearranged cancers.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Note 1 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Discussion of DepMap and CRISPRi screening
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Note 1 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Discussion of DepMap and CRISPRi screening
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Note 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Benchmarking ATM effect size against classical ATM regulators
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Note 2 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Benchmarking ATM effect size against classical ATM regulators
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 7 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Benchmarking ATM effect size against classical ATM regulators
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 7 from FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy
Benchmarking ATM effect size against classical ATM regulators